SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3442-3446. Prepublished online as a Blood First Edition Paper on January 12, 2006; DOI 10.1182/blood-2005-02-0833. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-02-0833v1 107/9/3442    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Treon, S. P. Articles by Stone, M. J. Search for Related Content PubMed PubMed Citation Articles by Treon, S. P. Articles by Stone, M. J. Related Collections Immunobiology Neoplasia Reviews in Translational Hematology Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLES Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia Steven P. Treon, Morie A. Gertz, Meletios Dimopoulos, Athanasios Anagnostopoulos, Joan Blade, Andrew R. Branagan, Ramon Garcia-Sanz, Stephen Johnson, Eva Kimby, Veronique LeBlond, Jean-Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, and Marvin J. Stone From the Bing Program for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Hematology, Mayo School of Medicine, Rochester MN; University of Athens School of Medicine, Athens, Greece; Hospital Clinic, Barcelona, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Taunton and Somerset Hospital, Somerset, United Kingdom; Huddinge University Hospital, Stockholm, Sweden; Hopital Pitie Salpetriere, Paris, France; Hopital Saint Louis, Paris, France; Fred Hutchinson Cancer Center, Seattle, WA; Scientific Institute Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy; Hospitalier Schaffner, Lens, France; Niguarda Ca'Granda Hospital, Milano, Italy; Columbia University, New York, NY; Universitario de Salamanca, Salamanca, Spain; Leeds General Infirmary, Leeds, United Kingdom; and Baylor Sammons Cancer Center, Dallas, TX. Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal gammopathy. As part of the Third International Workshop on WM, held October 7 to 10, 2004 in Paris, France, a consensus panel charged with providing treatment recommendations for WM updated its recommendations on both frontline and salvage therapies. The panel considered encouraging results from recent studies that addressed the use of extended-dose rituximab as well as other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or cyclophosphamide and dexamethasone. The panel determined that these were reasonable treatment options for WM patients and such therapeutic approaches were likely to yield results that are at least as good as if not better than the currently recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy. Such approaches were deemed to be reasonable treatment for WM patients in both the upfront and salvage settings, though randomized studies addressing the efficacy and toxicity of such novel approaches over previously established standard of care options are needed. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. P. Treon How I treat Waldenstrom macroglobulinemia Blood, September 17, 2009; 114(12): 2375 - 2385. [Abstract] [Full Text] [PDF] S. P. Treon, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, P. Sheehy, M. Nelson, M. Willen, J. Matous, J. Mattern II, J. G. Diener, et al. Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 J. Clin. Oncol., August 10, 2009; 27(23): 3830 - 3835. [Abstract] [Full Text] [PDF] P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al. International prognostic scoring system for Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4163 - 4170. [Abstract] [Full Text] [PDF] S. P. Treon, A. R. Branagan, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, B. Turnbull, P. Wasi, C. Emmanouilides, S. R. Frankel, A. Lister, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia Blood, April 16, 2009; 113(16): 3673 - 3678. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, A. Hoering, M. A. Gertz, S. Rivkin, J. Szymonifka, J. Crowley, and B. Barlogie Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003 Blood, January 22, 2009; 113(4): 793 - 796. [Abstract] [Full Text] [PDF] X. Leleu, L. Xu, X. Jia, A. Sacco, M. Farag, Z. R. Hunter, A.-S. Moreau, H. T. Ngo, E. Hatjiharissi, A. W. Ho, et al. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia Blood, January 15, 2009; 113(3): 626 - 634. [Abstract] [Full Text] [PDF] X. Leleu, J. Soumerai, A. Roccaro, E. Hatjiharissi, Z. R. Hunter, R. Manning, B. T. Ciccarelli, A. Sacco, L. Ioakimidis, S. Adamia, et al. Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom Macroglobulinemia Treated With Nucleoside Analogs J. Clin. Oncol., January 10, 2009; 27(2): 250 - 255. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, M. A. Gertz, E. Kastritis, R. Garcia-Sanz, E. K. Kimby, V. LeBlond, J.-P. Fermand, G. Merlini, P. Morel, E. Morra, et al. Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia J. Clin. Oncol., January 1, 2009; 27(1): 120 - 126. [Abstract] [Full Text] [PDF] S. P. Treon, J. D. Soumerai, A. R. Branagan, Z. R. Hunter, C. J. Patterson, L. Ioakimidis, L. Chu, P. Musto, A. D. Baron, J. C. Nunnink, et al. Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia Clin. Cancer Res., January 1, 2009; 15(1): 355 - 360. [Abstract] [Full Text] [PDF] S. P. Treon, J. D. Soumerai, A. R. Branagan, Z. R. Hunter, C. J. Patterson, L. Ioakimidis, F. M. Briccetti, M. Pasmantier, H. Zimbler, R. B. Cooper, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia Blood, December 1, 2008; 112(12): 4452 - 4457. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, E. Kastritis, S. Delimpassi, A. Zomas, M. C. Kyrtsonis, and K. Zervas The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens Haematologica, September 1, 2008; 93(9): 1420 - 1422. [Full Text] [PDF] A. M. Roccaro, X. Leleu, A. Sacco, X. Jia, M. Melhem, A.-S. Moreau, H. T. Ngo, J. Runnels, A. Azab, F. Azab, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia Blood, May 1, 2008; 111(9): 4752 - 4763. [Abstract] [Full Text] [PDF] A. M. Roccaro, X. Leleu, A. Sacco, A.-S. Moreau, E. Hatjiharissi, X. Jia, L. Xu, B. Ciccarelli, C. J. Patterson, H. T. Ngo, et al. Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstrom's Macroglobulinemia Clin. Cancer Res., March 15, 2008; 14(6): 1849 - 1858. [Abstract] [Full Text] [PDF] X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Blood, December 15, 2007; 110(13): 4417 - 4426. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, A. Anagnostopoulos, M.-C. Kyrtsonis, K. Zervas, C. Tsatalas, G. Kokkinis, P. Repoussis, A. Symeonidis, S. Delimpasi, E. Katodritou, et al. Primary Treatment of Waldenstrom Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide J. Clin. Oncol., August 1, 2007; 25(22): 3344 - 3349. [Abstract] [Full Text] [PDF] B. Asli, B. Bienvenu, F. Cordoliani, J.-C. Brouet, Y. Uzunhan, B. Arnulf, M. Malphettes, M. Rybojad, and J.-P. Fermand Chronic Urticaria and Monoclonal IgM Gammopathy (Schnitzler Syndrome): Report of 11 Cases Treated With Pefloxacin Arch Dermatol, August 1, 2007; 143(8): 1046 - 1050. [Abstract] [Full Text] [PDF] A. Vijay and M. A. Gertz Waldenstrom macroglobulinemia Blood, June 15, 2007; 109(12): 5096 - 5103. [Abstract] [Full Text] [PDF] S. P. Treon, Z. R. Hunter, J. Matous, R. M. Joyce, B. Mannion, R. Advani, D. Cook, J. Songer, J. Hill, B. R. Kaden, et al. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248 Clin. Cancer Res., June 1, 2007; 13(11): 3320 - 3325. [Abstract] [Full Text] [PDF] A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia Blood, June 1, 2007; 109(11): 4964 - 4972. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020